Inhibition of mammary carcinoma cell growth by RXR is mediated by the receptor's oligomeric switch

Journal of Molecular Biology

Volumn 397, Issue 5, 2010, Pages 1121-1131

  Yasmin, Rubina ^a   Kannan Thulasiraman, Padmamalini ^a   Kagechika, Hiroyuki ^b   Dawson, Marcia I ^c   Noy, Noa ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c BURNHAM INSTITUTE   (United States)

Author keywords

DNA architecture; Growth inhibition; Rexinoid; RXR; Tetramer

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 9; CYCLIN D1; DNA; GENE PRODUCT; PA 452; PROTEIN BTG2; RETINOID X RECEPTOR; RETINOID X RECEPTOR ANTAGONIST; SR 11345; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENE SILENCING; GEOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 77950521484     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2010.02.030     Document Type: Article

References (29)

1. Germain P., Chambon P., Eichele G., Evans R.M., Lazar M.A., Leid M., et al. International Union of Pharmacology: LXIII. Retinoid X receptors. Pharmacol. Rev. 2006, 58:760-772.
2. Dilworth F.J., Chambon P. Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription. Oncogene 2001, 20:3047-3054.
3. Kersten S., Gronemeyer H., Noy N. The DNA binding pattern of the retinoid X receptor is regulated by ligand-dependent modulation of its oligomeric state. J. Biol. Chem. 1997, 272:12771-12777.
4. Kersten S., Kelleher D., Chambon P., Gronemeyer H., Noy N. Retinoid X receptor alpha forms tetramers in solution. Proc. Natl Acad. Sci. USA 1995, 92:8645-8649.
5. Kersten S., Pan L., Chambon P., Gronemeyer H., Noy N. Role of ligand in retinoid signaling. 9-cis-Retinoic acid modulates the oligomeric state of the retinoid X receptor. Biochemistry 1995, 34:13717-13721.
6. Kersten S., Pan L., Noy N. On the role of ligand in retinoid signaling: positive cooperativity in the interactions of 9-cis retinoic acid with tetramers of the retinoid X receptor. Biochemistry 1995, 34:14263-14269.
7. Gampe R.T., Montana V.G., Lambert M.H., Wisely G.B., Milburn M.V., Xu H.E. Structural basis for autorepression of retinoid X receptor by tetramer formation and the AF-2 helix. Genes Dev. 2000, 14:2229-2241.
8. Kersten S., Dong D., Lee W., Reczek P.R., Noy N. Auto-silencing by the retinoid X receptor. J. Mol. Biol. 1998, 284:21-32.
9. Kersten S., Reczek P.R., Noy N. The tetramerization region of the retinoid X receptor is important for transcriptional activation by the receptor. J. Biol. Chem. 1997, 272:29759-29768.
10. Yasmin R., Yeung K.T., Chung R.H., Gaczynska M.E., Osmulski P.A., Noy N. DNA-looping by RXR tetramers permits transcriptional regulation "at a distance". J. Mol. Biol. 2004, 343:327-338.
11. Gottardis M.M., Bischoff E.D., Shirley M.A., Wagoner M.A., Lamph W.W., Heyman R.A. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res. 1996, 56:5566-5570.
12. Bischoff E.D., Gottardis M.M., Moon T.E., Heyman R.A., Lamph W.W. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res. 1998, 58:479-484.
13. Wu K., Zhang Y., Xu X.C., Hill J., Celestino J., Kim H.T., et al. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res. 2002, 62:6376-6380.
14. Agarwal V.R., Bischoff E.D., Hermann T., Lamph W.W. Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (targretin). Cancer Res. 2000, 60:6033-6038.
15. Breneman D., Duvic M., Kuzel T., Yocum R., Truglia J., Stevens V.J. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch. Dermatol. 2002, 138:325-332.
16. Duvic M., Martin A.G., Kim Y., Olsen E., Wood G.S., Crowley C.A., Yocum R.C. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch. Dermatol. 2001, 137:581-593.
17. Esteva F.J., Glaspy J., Baidas S., Laufman L., Hutchins L., Dickler M., et al. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J. Clin. Oncol. 2003, 21:999-1006.
18. Kong G., Kim H.T., Wu K., DeNardo D., Hilsenbeck S.G., Xu X.C., et al. The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Res. 2005, 65:3462-3469.
19. Steinmetz A.C., Renaud J.P., Moras D. Binding of ligands and activation of transcription by nuclear receptors. Annu. Rev. Biophys. Biomol. Struct. 2001, 30:329-359.
20. Kawakubo H., Brachtel E., Hayashida T., Yeo G., Kish J., Muzikansky A., et al. Loss of B-cell translocation gene-2 in estrogen receptor-positive breast carcinoma is associated with tumor grade and overexpression of cyclin d1 protein. Cancer Res. 2006, 66:7075-7082.
21. Donato L.J., Suh J.H., Noy N. Suppression of mammary carcinoma cell growth by retinoic acid: the cell cycle control gene Btg2 is a direct target for retinoic acid receptor signaling. Cancer Res. 2007, 67:609-615.
22. Iwata M., Eshima Y., Kagechika H. Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors. Int. Immunol. 2003, 15:1017-1025.
23. Panariello L., Quadro L., Trematerra S., Colantuoni V. Identification of a novel retinoic acid response element in the promoter region of the retinol-binding protein gene. J. Biol. Chem. 1996, 271:25524-25532.
24. Donato L.J., Noy N. Suppression of mammary carcinoma growth by retinoic acid: proapoptotic genes are targets for retinoic acid receptor and cellular retinoic acid-binding protein II signaling. Cancer Res. 2005, 65:8193-8199.
25. Poujol N., Margeat E., Baud S., Royer C.A. RAR antagonists diminish the level of DNA binding by the RAR/RXR heterodimer. Biochemistry 2003, 42:4918-4925.
26. Li Y., Hashimoto Y., Agadir A., Kagechika H., Zhang X. Identification of a novel class of retinoic acid receptor beta-selective retinoid antagonists and their inhibitory effects on AP-1 activity and retinoic acid-induced apoptosis in human breast cancer cells. J. Biol. Chem. 1999, 274:15360-15366.
27. Dawson M.I., Jong L., Hobbs P.D., Cameron J.F., Chao W.R., Pfahl M., et al. Conformational effects on retinoid receptor selectivity: 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity. J. Med. Chem. 1995, 38:3368-3383.
28. Ebisawa M., Umemiya H., Ohta K., Fukasawa H., Kawachi E., Christoffel G., et al. Retinoid X receptor-antagonistic diazepinylbenzoic acids. Chem. Pharm. Bull. (Tokyo) 1999, 47:1778-1786.
29. Umemiya H., Fukasawa H., Ebisawa M., Eyrolles L., Kawachi E., Eisenmann G., et al. Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers. J. Med. Chem. 1997, 40:4222-4234.